Sq Innovation

SQ Innovation is a privately-held Swiss biopharmaceutical company located in Zug, Switzerland, Burlington, MA, and Rotterdam, The Netherlands. The company was established to develop and commercialize innovative cost-effective therapies for subcutaneous delivery of pharmaceutical products where and when needed. Its first product was designed specifically for the treatment of fluid overload due to worsening heart failure. The product called Lasix ONYU was approved by the US FDA on October 7 2025. The innovative combination product is based on a novel high-concentration formulation and uses a cost-effective two-component device design. The device was designed with the patient, provider, payor and environment in mind. The Infusor uses a reusable motorized component and a disposable component. The company's products are subject to regulatory review and approval.